Rhythm Pharmaceuticals, Inc. (RYTM) Revenue, Earnings & Financial Statements
$116.61NASDAQ: RYTMMarket Cap $8.08B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Rhythm Pharmaceuticals, Inc. most recently reported annual revenue of $190.0M, a net loss of $197.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Rhythm Pharmaceuticals, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -5391.9% to -101.2%, a shift of +5290.7 percentage points; the most recent year shows a net loss of $197.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$3.0M
$24.0M
$77.0M
$130.0M
$190.0M
Operating Expenses
$26.0M
$32.0M
$78.0M
$146.0M
$137.0M
$173.0M
$203.0M
$262.0M
$396.0M
$382.0M
Operating Profit
−$26.0M
−$32.0M
−$78.0M
−$146.0M
−$137.0M
−$170.0M
−$179.0M
−$184.0M
−$266.0M
−$192.0M
Operating Margin
—
—
—
—
—
-5391.9%
-757.9%
-238.1%
-204.0%
-101.2%
Other Income
$0
−$1.0M
$4.0M
$5.0M
$3.0M
$100.0M
−$2.0M
$0
$5.0M
−$4.0M
Interest
$0
$0
$0
$0
$0
$0
$5.0M
$14.0M
$21.0M
$21.0M
Depreciation
$0
$0
$0
$1.0M
$1.0M
$1.0M
$2.0M
$2.0M
$2.0M
$1.0M
Profit Before Tax
−$26.0M
−$34.0M
−$74.0M
−$141.0M
−$134.0M
−$70.0M
−$181.0M
−$184.0M
−$260.0M
−$196.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
-0.3%
-0.1%
-0.3%
Net Profit
−$26.0M
−$34.0M
−$74.0M
−$135.0M
−$131.0M
−$70.0M
−$181.0M
−$185.0M
−$261.0M
−$197.0M
EPS
−$1.55
−$1.26
−$2.39
−$3.70
−$2.96
−$1.37
−$3.51
−$3.20
−$4.34
−$3.11
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$24.0M
$26.0M
$29.0M
$33.0M
$42.0M
$33.0M
$49.0M
$51.0M
$57.0M
$60.0M
$71.0M
$92.0M
Operating Expenses
$65.0M
$166.0M
$70.0M
$77.0M
$83.0M
$80.0M
$94.0M
$104.0M
$104.0M
$112.0M
$120.0M
$131.0M
Operating Profit
−$41.0M
−$140.0M
−$40.0M
−$44.0M
−$41.0M
−$47.0M
−$45.0M
−$53.0M
−$47.0M
−$52.0M
−$49.0M
−$39.0M
Operating Margin
-170.3%
-538.7%
-139.2%
-132.0%
-98.6%
-143.7%
-93.4%
-102.6%
-82.2%
-87.1%
-68.1%
-42.6%
Interest
$5.0M
$5.0M
$5.0M
$5.0M
$5.0M
$5.0M
$6.0M
$5.0M
$5.0M
$5.0M
$5.0M
$4.0M
Profit Before Tax
−$41.0M
−$141.0M
−$32.0M
−$44.0M
−$43.0M
−$49.0M
−$46.0M
−$53.0M
−$48.0M
−$55.0M
−$49.0M
−$41.0M
Tax rate (%)
-0.5%
-0.2%
-1.5%
0.8%
0.2%
-0.2%
-0.7%
-0.2%
0.1%
-1.0%
-0.9%
-1.5%
Net Profit
−$42.0M
−$141.0M
−$32.0M
−$44.0M
−$43.0M
−$49.0M
−$47.0M
−$53.0M
−$48.0M
−$56.0M
−$49.0M
−$41.0M
EPS
−$0.70
−$2.35
−$0.53
−$0.71
−$0.72
−$0.81
−$0.75
−$0.82
−$0.73
−$0.83
−$0.73
−$0.61
Over the 10 years reported for Rhythm Pharmaceuticals, Inc., cash stood at $54.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.41 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$12.0M
$152.0M
$260.0M
$309.0M
$187.0M
$330.0M
$382.0M
$333.0M
$392.0M
$480.0M
Current Assets
$11.0M
$151.0M
$259.0M
$302.0M
$182.0M
$308.0M
$354.0M
$308.0M
$374.0M
$467.0M
Cash
$7.0M
$34.0M
$50.0M
$62.0M
$101.0M
$59.0M
$128.0M
$60.0M
$89.0M
$54.0M
Inventory
$0
$0
$0
$0
$0
$0
$3.0M
$9.0M
$19.0M
$26.0M
Receivables
$0
$0
$0
$0
$0
$1.0M
$6.0M
$15.0M
$19.0M
$26.0M
Fixed Assets
$1.0M
$1.0M
$1.0M
$6.0M
$5.0M
$4.0M
$3.0M
$2.0M
$4.0M
$4.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$4.0M
$114.0M
$203.0M
$230.0M
$72.0M
$236.0M
$206.0M
$216.0M
$231.0M
$335.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$5.0M
$7.0M
$14.0M
$28.0M
$21.0M
$45.0M
$118.0M
$163.0M
$228.0M
$210.0M
Current Liabilities
$5.0M
$7.0M
$14.0M
$24.0M
$18.0M
$43.0M
$40.0M
$55.0M
$116.0M
$106.0M
Borrowings
$0
$0
$0
$4.0M
$3.0M
$3.0M
$2.0M
$1.0M
$4.0M
$4.0M
Other Liabilities
$5.0M
$7.0M
$14.0M
$24.0M
$17.0M
$43.0M
$116.0M
$162.0M
$224.0M
$206.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$7.0M
$145.0M
$246.0M
$281.0M
$167.0M
$284.0M
$264.0M
$170.0M
$165.0M
$270.0M
For Rhythm Pharmaceuticals, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $117.0M; free cash flow was positive in 0 of 10 years; financing activities used $20.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$23.0M
−$29.0M
−$62.0M
−$123.0M
−$122.0M
−$146.0M
−$173.0M
−$136.0M
−$114.0M
−$116.0M
Investing Cash Flow
−$10.0M
−$220.0M
−$174.0M
−$31.0M
$158.0M
−$68.0M
$24.0M
−$6.0M
−$48.0M
−$138.0M
Financing Cash Flow
$0
$1.0M
$2.0M
$2.0M
$2.0M
$5.0M
$83.0M
$25.0M
$13.0M
−$20.0M
Net Cash Flow
−$28.0M
$28.0M
$15.0M
$13.0M
$39.0M
−$42.0M
$68.0M
−$68.0M
$29.0M
−$35.0M
Free Cash Flow
−$24.0M
−$30.0M
−$63.0M
−$126.0M
−$122.0M
−$151.0M
−$178.0M
−$136.0M
−$114.0M
−$117.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-6.04
EV / EBITDA
-44.68
FCF Yield
-1.64%
Quick Ratio
2.57
Interest Coverage
-10.27
Return 1Y
15.81%
Return 3Y
244.80%
Return 5Y
919.32%
Rhythm Pharmaceuticals, Inc. (RYTM) financials — frequently asked questions
What is Rhythm Pharmaceuticals, Inc.'s annual revenue?
Rhythm Pharmaceuticals, Inc. (RYTM) reported annual revenue of $190.0M in its most recent fiscal year.
What is Rhythm Pharmaceuticals, Inc.'s net profit?
Rhythm Pharmaceuticals, Inc. (RYTM) reported a net loss of $197.0M in its most recent fiscal year.
What is RYTM EV/EBITDA?
Rhythm Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -44.68. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks